Back to top
more

bioAffinity Technologies, Inc. (BIAF)

(Delayed Data from NSDQ)

$0.30 USD

0.30
750,313

-0.01 (-1.94%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $0.30 0.00 (0.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

The Zacks Analyst Blog Highlights Meta Platforms, ServiceNow, Booking, Vaso and bioAffinity Technologies

by Zacks Equity Research

META, NOW, and BKNG lead with AI-driven growth and digital transformation tailwinds, while VASO and BIAF offer speculative upside.

Mark Vickery headshot

Top Research Reports for Meta Platforms, ServiceNow & Booking

by Mark Vickery

META, NOW, and BKNG gain ground as AI, digital transformation, and global travel trends fuel top-line momentum.

Zacks Equity Research

BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline

by Zacks Equity Research

bioAffinity's first-quarter 2025 results show CyPath Lung sales growth and cost cuts despite a drop in total revenues and a wider quarterly net loss.

Zacks Equity Research

The Zacks Analyst Blog Highlights Alphabet, Berkshire Hathaway, Visa and bioAffinity Technologies

by Zacks Equity Research

Alphabet, Berkshire Hathaway, Visa and bioAffinity Technologies are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Alphabet, Berkshire Hathaway & Visa

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Berkshire Hathaway Inc. (BRK.B) and Visa Inc. (V), as well as a micro-cap stock bioAffinity Technologies, Inc. (BIAF).

Zacks Equity Research

BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues

by Zacks Equity Research

bioAffinity witnesses record 2024 revenues, driven by CyPath Lung adoption, Medicare coverage and strategic expansion across healthcare networks.

Debanjana Dey headshot

Zacks Initiates Coverage of bioAffinity With Neutral Recommendation

by Debanjana Dey

Discover why Zacks rates bioAffinity as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore BIAF's promising growth prospects and financial health amid market challenges.

Zacks Equity Research

The Zacks Analyst Blog Highlights Amazon, Bank of America, Caterpillar, NVE and bioAffinity

by Zacks Equity Research

Amazon, Bank of America, Caterpillar, NVE and bioAffinity are included in this Analyst Blog.